Biotechnology company Cantargia AB (publ) announced on Monday that it has entered into a supply agreement with Patheon Biologics BV (part of ThermoFischer Scientific) with regard to future production of the antibody CAN04 (nidanilimab), which is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer.

Under the agreement, Cantargia secures additional production capacity for future clinical trials.

CAN04 is being investigated in a European phase IIa clinical trial and the company said that increased production capacity is part of the development plan in order to prepare for late stage clinical trials.

Cantargia added that the new supply agreement with Patheon, which has manufacturing facilities in both Europe and USA, complements the current agreement with Celonic AG (formerly Glycotope Biotechnology GmbH). Patheon will scale up the process to 2000 litres before next production campaign of clinical material.